Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for October 2008
October 1, 2008
- Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien Study
- Critical Pharmaceuticals Enter Sustained Release hGH Arena
- ImmunoVaccine Technologies' DepoVax Shows Positive Results for Cancer and Infectious Diseases
- Amgen Receives Executive Summary from Independent Cochrane Collaboration Review of ESAs in Oncology
- Dicerna Pharmaceuticals Announces Preclinical Findings Highlighting Novel Approach to Maximizing Dicer-Substrate Small Interfering RNAs (DsiRNAs) in Rheumatoid Arthritis; Data Appear Published by Molecular Therapy
- Watson Announces Positive Data for RAPAFLO(silodosin), Its Investigational Product for BPH, at Regional AUA Conferences
- Idera Pharmaceuticals Announces Preliminary Data from Phase 2a Clinical Study of IMO-2055 Monotherapy in Renal Cell Carcinoma
- Apthera Announces Optimal Dose and Schedule of NeuVax for Phase III Clinical Trial in Breast Cancer
- Tranzyme Pharma Announces Positive Phase IIb Results with Its Ghrelin Agonist, TZP-101, for Postoperative Ileus (POI)
- A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV
October 2, 2008
- Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
- Access Pharmaceuticals Presents New Data on the Company's Angiolix Therapeutic Monoclonal Antibody
- Journal: Scientists Identify Successful 'Anti' Antibiotic That May Help Curb Rising Staph Infections
- Provectus Lead Investigator Professor John F. Thompson Presents at “Perspectives in Melanoma XII” Conference
October 3, 2008
- Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
- New Publication Shows Cleviprex Provides More Precise Blood Pressure Control in Cardiac Surgery Patients
- New Chemotherapy ‘Cures’ Early Testicular Cancer
- MaxCyte to Present at AABB Annual Meeting & TXPO 2008 in Montreal, Quebec, Canada
October 6, 2008
- New Findings Show Efficacy of Remicade Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study
- CombinatorX Announces Top-Line Results from Phase 2b Study of Synavive (CRx-102) for Knee Osteoarthritis
- COPD Landmark UPLIFT trial proves tiotropium significantly reduces risk of death, improves quality of life, sustains lung function improvements over four years
- Genta Updates Progress of its Phase 3 Trial of Genasense in Patients with Advanced Melanoma AGENDA Trial Expected to Complete Accrual Early 2009
- Orexigen Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave
- Dendreon Announces Interim Data from Phase 3 Provenge IMPACT Trial
- Dendreon Announces Interim Data From Phase 3 Provenge IMPACT Trial
- Shire Announces Results from a Multidisciplinary Analysis of the Drug Release Profiles of LIALDA (mesalamine) and Asacol (mesalamine) for the Treatment of Ulcerative Colitis (UC) at the American College of Gastroenterology (ACG) Meeting
- Cortex's Ampakine Compound, CX717, Achieves Primary Endpoints in Second Phase IIa Respiratory Depression Study in Germany
- Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
- Cimzia (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
- Salix Presents New Phase II Data Evidence Demonstrating the Clinical Utility of Rifaximin in Irritable Bowel Syndrome (IBS)
- Bayer Reports Progress in Clinical Program for Riociguat
- Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
- Provectus Lead Investigator Professor John F. Thompson Gives Update on PV-10 Phase 2 Study
- Salix Presents New Phase II Data Evidence Demonstrating the Clinical Utility of Rifaximin in Irritable Bowel Syndrome (IBS)
- Video: COPD Landmark Trial UPLIFT Proves Tiotropium Sustains Lung Function Improvements Over Four Years and Improves Survival Rate
- Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
- VIVUS Announces the Weight Loss Effects of Qnexa in Type 2 Diabetes
- Cortex’s AMPAKINE Compound, CX717, Achieves Primary Endpoints in Second Phase IIa Respiratory Depression Study in Germany
October 7, 2008
- New Phase II data on NVA237, a novel once-daily treatment for COPD, show promising efficacy and tolerability with potentially faster onset than tiotropium
- Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
- Bavarian Nordic announces positive mature Phase II results from newly acquired prostate cancer vaccine
- NVA237 Phase II results presented at the European Respiratory Society Annual Meeting show promising efficacy and tolerability with potentially faster onset than tiotropium
- Data Show Aerovance's Aerovant Inhalation Powder is Well Tolerated in Asthma Patients
- NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
- Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
- Cimzia (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients
- Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
- In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop
- Media Advisory: New Amitiza (lubiprostone) and Irritable Bowel Syndrome with Constipation Data Presented at the American College of Gastroenterology 2008 Annual Meeting Expands Breadth and Depth of State of the Science
- Orexigen Therapeutics Reviews Significant Data Regarding Its Obesity Product Candidates
- Study Published in Journal of Clinical Psychiatry Showed Once-Daily Vyvanse (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
- Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
- Pivotal Phase III study shows MabThera delays disease progression in patients with relapsed or refractory Chronic Lymphocytic Leukaemia
- Study Shows EUFLEXXA Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
- Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
- Biovest Announces BiovaxID Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44%
- Advaxis Incorporated Collaborates on Groundbreaking Listeria Moncoytogenes Immunotherapy Research Discovery
October 8, 2008
- Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
- Vical Expands Applications of Vaxfectin Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
- LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease
- Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
- Omrix Biopharmaceuticals Announces Interim Analysis Indicating Superiority of Fibrin Pad Versus SURGICEL in Mild to Moderate Bleeding In U.S. Phase II Clinical Trial And Provides Update On Additional Fibrin Pad Clinical Trials
- NovaBay Pharmaceuticals To Present Data On Lead Anti-Infective Compound at First-Ever ICAAC/IDSA Joint Meeting
- Use Of Medication For Enlarged Prostate Not Associated With Increased Risk Of Hip Fracture
- Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference
- Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference
- Health Discovery Corporation's New Prostate Cancer Test is Ready for Commercialization Following Successful Completion of Final Clinical Trials
- One Year of GATTEX Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome
- Protox Announces Positive 12 Month Data from BPH Study
- Viral Genetics, Inc. Invited to Present New Model, Initial Findings of Lyme Disease Study at Prestigious ILADS Conference
October 9, 2008
- Diamyd Study Published in Prestigious New England Journal of Medicine
- Paper in Cell Cycle Reports Alfacell's ONCONASE Targets siRNA
- Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at the 15th International Symposium on Hepatitis C Virus and Related Viruses
- MIV Therapeutics Announces Participation at TCT 2008 in Washington, D.C.
- Clinical Data from 'OPEN I' Study of the Stentys Stent to Be Reported at Next Week's 'TCT 2008' International Cardiovascular Meeting
October 10, 2008
- Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis
- Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of Taxus Coronary Stent Systems at TCT 2008
- Nymox NX-1207 Successful Clinical Trial Results Featured in Urology Times
- The Micell Rapid Absorption Polymer DES System to be Presented at TCT 2008
October 13, 2008
- GTx Announces Investigational Ostarine (MK-2866) Met the Primary Endpoint in the Phase II Cancer Cachexia Clinical Trial
- Archimedes Pharma Announces First Positive Phase III Clinical Trial Results for NasalFent
- Peregrine Pharmaceuticals' anti-PS Technology Platform to Be Discussed at AIDS Vaccine 2008 Conference
- iCo Therapeutics Provides iCo-009 (Oral Amphotericin B) Pharmacokinetic Results
- Kamada Reports Positive Phase II Data with Inhaled AAT in Cystic Fibrosis
- Avontec announces the results of a successful proof of concept within a phase 2a study with its drug candidate AVT-02 UE ointment after topical treatment in patients with mild-to-moderate psoriasis
- New Data Shows Abbott's Bioabsorbable Drug Eluting Stent is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels
- SUVN-502 data being presented at 16th BioPartnering in London
- Revotar reports positive Phase I data in psoriasis with its Bimosiamose 5% Cream
- Acura Pharmaceuticals And King Pharmaceuticals Announce Positive Top Line Results Of Key Clinical Study Assessing Abuse Liability
- Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
- TAXUS Express Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
- New Data on Medtronic's ENDEAVOR Drug-Eluting Coronary Stent Shows Strong Performance in Complex Patients and Durable Efficacy
- First Heart Failure Patients Successfully Implanted with Angioblast Systems' "Off-the-Shelf" Adult Stem Cells
- 12-Month ATLANTA Trial Data Show Sustained Benefit of Catania Stent in Treatment of De Novo Coronary Lesions
- Medtronic's Third-Generation Endeavor Resolute Drug-Eluting Stent Maintains Strong Efficacy and Safety Profile at Two Years
- Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent
- XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
- Medtronic Announces Plans to Release Data on Broad Portfolio of Cardiovascular Innovations at TCT 2008
- Abbott's XIENCE V Drug Eluting Stent Outperforms TAXUS in Key Efficacy and Safety Endpoints Out to Two Years
- Fast Treatment Can Reverse Progress of Newly Recognized Disease Anti-NMDA Receptor Encephalitis and its Related Tumor
October 14, 2008
- Neurogen Announces Positive Results for Aplindore in Restless Legs Syndrome and Parkinson's Disease
- Aradigm Completes Enrollment in Phase 2 Study of Inhaled Liposomal Ciprofloxacin for Bronchiectasis
- HemCon Medical Technologies, Inc. Announces Promising Results from Nail Anti-Fungal Study
- Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
- Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous Bio-engineered R stent
- Astex Presents Updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference
- Neurogen Announces Positive Results for Aplindore in Restless Legs Syndrome and Parkinson's Disease
- Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
- Long-Term Follow-Up Data Confirm Cox-2 Inhibitor Rofecoxib Substantially Increases Risk of Stroke, Heart Attack, And Death
- Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol
- Nu Skin Scientists Correlate the Appearance of Aging With arNOX Free Radical Generator
- Provectus Announces First Peer-Reviewed Publication on PV-10 in "Melanoma Research"
- The Medicines Company Announces HORIZONS-AMI 1-Year Data To Be Presented at 2008 TCT Meeting
- VaxInnate to Present Positive Results from Clinical Trial of Universal Flu Vaccine Candidate at ICAAC/IDSA Meeting
- Sustained Safety Profile of Medtronic's Endeavor Drug-Eluting Stent Differentiates It from Other DES
- ImmunoGen, Inc. Announces Presentations at Upcoming EORTC-NCI-AACR Symposium
- Endeavor Vs. Taxus: Medtronic's Drug-Eluting Coronary Stent Linked to Fewer Heart Attacks at Two Years Post Implant
- SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS Express2 Stents and Bypass Surgery
October 15, 2008
- Lexicon to Present Clinical Data for LX2931, an Investigational New Drug for Rheumatoid Arthritis
- Phase 1 Clinical Trial Results of Anti-MRSA Drug Presented at ICAAC/IDSA
- New Class of Drug Candidates Developed by Santaris Pharma Can Potently Counteract Disease-Associated MicroRNAs
- TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated with Second-Generation TAXUS Liberte Stent
- Geron's GRN163L Sensitizes Resistant Breast Cancer Cells to Trastuzumab in Preclinical Study
- VGX Pharmaceuticals Presents Non-Human Primate Study Data at AIDS Vaccine 2008 Conference
- HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS Drug-Eluting Stents in Heart Attack Patients
- Angiomax Reduced Cardiac Mortality by 43 Percent and Improved Overall Survival by 31 Percent at One-Year in HORIZONS-AMI Trial
- Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
- Savient to Host Conference Call on Pegloticase Scientific Presentations
- University of Ottawa Heart Institute Trial Finds Popular Blood Clotting Drug Does Not Improve Patient Outcomes and Increases Risk of Bleeding
- Angiomax_ Reduced Cardiac Mortality By 43 Percent And Improved Overall Survival By 31 Percent In Horizons/AMI Trial
October 16, 2008
- Idera Pharmaceuticals Presents Data from Autoimmune Disease Program at 4th Annual Meeting of the Oligonucleotide Therapeutics Society
- EPIX Pharmaceuticals to Present at the Alzheimer's Association Research Roundtable Meeting
- GTx Announces Presentation of Toremifene 80 mg Data at Fourth Annual Chicago Supportive Oncology Conference
- Alnylam Scientists Present Data from Multiple Programs at the 4th Annual Meeting of the Oligonucleotide Therapeutics Society
- Tranzyme Pharma's Ghrelin Agonist TZP-101 Shows Potential as a Potent Agent for Cancer Cachexia
- Exelixis Submits Diligence Report for Cdc7 Inhibitor to Bristol-Myers Squibb
- BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
- Cytopia Scientific Presentations on JAK2 Inhibitor Program
- SDI Reports: Patients in the Midwest Taking Anti-Seizure Medications Prescribed by a Neurologist Maintain Therapy 16% Longer Than the National Average
- NPS Pharmaceuticals Announces Multiple GATTEX Data Presentations at 16th United European Gastroenterology Week Meeting
- Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin’s Lymphoma
- Obagi Medical Products' ELASTIderm Decolletage System Reduces Visible Signs of Aging on Chest and Neck
- GeoVax Presents Data at AIDS Vaccine 2008 Conference
- NPS Pharmaceuticals Announces Multiple Gattex Data Presentations at 16th United European Gastroenterology Week Meeting
- Zafgen Inc. to Present at First Annual Boston Biotech R&D Conference
- Enzon to Present Data at EORTC-NCI-AACR
- Elixir Medical Corporation Announced Positive First-In-Man Results from Three Drug Eluting Coronary Stent Systems
- Exelixis Will Have 15 Presentations at the 2008 EORTC-NCI-AACR Annual Meeting
- Gemin X Announces Data Presentations for its Novel, Targeted Cancer Therapies Obatoclax and GMX1777 at the 20th Annual EORTC-NCI-AACR Symposium
- Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma
- Study in Today's New England Journal of Medicine Suggests Benefits of Genzyme’s Thymoglobulin Sustained Through Five Years in Kidney Transplant Patients
- ARIAD to Present Data on Deforolimus and AP24534 at 20th Annual EORTC-NCI-AACR Symposium
- Isotechnika Partner Invited to Present on Drug Eluting Stent Trial Using Voclosporin
October 17, 2008
- Positive Phase II Data on Cougar Biotechnology's CB7630 Presented at Prostate Cancer Foundation Scientific Retreat
- New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
- Danish Study Supports Efficacy of Endeavor Stent
- Preliminary Phase I Safety Data for Preventive HIV Vaccine Delivered by Ichor's TriGrid to be Presented at AIDS Conference
- Telavancin Data to be Presented at Upcoming Scientific Conferences
October 20, 2008
- NanoViricides, Inc. Participated In WHO Meeting On Dengue Therapeutics
- Basilea announces new data to be presented on ceftobiprole and isavuconazole at ICAAC/IDSA
- Vertex Announces Positive 28-Day Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cystic Fibrosis
- MediGene Reports Positive Final Results from EndoTAG-1 Phase II Study in Pancreatic Cancer
- Acterma (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting
- Data from Optimer Pharmaceuticals' Prulifloxacin Phase 3 Trial in Traveler's Diarrhea and Strain Typing Data from OPT-80 Study to be Presented at ICAAC/IDSA Annual Meeting
- Enzon Presents New Data on Its LNA Programs
- Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
- Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
- Senesco's Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'
- ONSOLIS (BEMA Fentanyl) Data to be Presented at the American Society of Anesthesiologists (ASA) Annual Meeting
- Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
- TaiGen Announces Presentation of Nemonoxacin at the Joint Meeting of ICAAC/IDSA
- Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
- High-Dose Zevalin With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
- Array BioPharma to Present Clinical Data at the 2008 ACR/ARHP Annual Scientific Meeting
- Statins Reduce Risk of Alzheimer's Disease According to New Long-Term Prospective Study
October 21, 2008
- Cyclacel to Present Preclinical Data Showing Synergy of Combination of Sapacitabine with Histone Deacetylating Agents
- EPIX Pharmaceuticals to Present at the North American Cystic Fibrosis Conference
- Poor Perioperative Blood Pressure Control Linked to 30-Day Morbidity and Mortality in Cardiac Surgery Patients
- Avigen Announces AV650 Did Not Meet Efficacy Endpoints in Phase 2b Clinical Trial for Spasticity in Patients With Multiple Sclerosis
- Sucampo Europe Presents Long-Term Safety and Efficacy Data of Lubiprostone in Chronic Idiopathic Constipation
- CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
- Access Pharmaceuticals Presents ProLindac Data at the AACR-NCI-EORTC Symposium 2008
- Peregrine Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
- Viral Genetics, Inc. Releases Initial Findings of Lyme Disease Study
- Sunesis Announces Multiple Clinical Data Presentations
- Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call
- NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008
- Aiming at Multiple Alzheimer's Proteins May be Key to Success
- Argos Therapeutics Publishes Approach to Generating High-Avidity Cytotoxic T Cells with Dendritic Cell-Based Immunotherapy
October 22, 2008
- Targanta Therapeutics Releases Results from Phase 2 SIMPLIFI Study Evaluating Single or Infrequent Doses of Oritavancin
- Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
- Exelixis Reports Positive Phase 1 Data for PI3K/mTOR Inhibitor XL765 at EORTC-NCI-AACR Symposium
- ZymoGenetics Presents Interim IL-21 Phase 2 Results in Renal Cell Cancer
- Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
- Redpoint Bio Researchers Develop Method of Measuring and Classifying Bitterness in a Broad Range of Orally Aversive Pharmaceuticals
- Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
- Nexium (esomeprazole) First PPI to Demonstrate Sustained Reduction in Peptic Ulcer Re-Bleeding in Large Scale Multinational Placebo-Controlled Clinical Study
- Clinical Study of Intermezzo for the Treatment of Middle of the Night Awakening Published in SLEEP
- PARI Respiratory to Present New Study Comparing Nebulizers Delivering Budesonide at CHEST 2008
- Independent Study Reveals Synvisc Offers Longer Knee Pain Relief and Greater Patient Satisfaction for Knee Osteoarthritis
- AdvanDx's PNA FISH Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
- Exelixis Reports Positive Phase 1 Data for PI3K Inhibitor XL147 at EORTC-NCI-AACR Symposium
- Persistent Vaccination Effect of Grazax After Completion of Treatment
- Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on 'Molecular Targets and Cancer Therapeutics' Demonstrate Superior Profile of S*BIO's Novel Anti-Cancer Drug SB939
- ERYtech Pharma Proposes New Anticancer Vaccine Technology
- Aileron Advances First Stapled Peptide Drug Candidate that Targets Newly-Discovered BAX Activation Mechanism
- Tekmira Pharmaceuticals Announces Presentation of Data Using SNALP RNAi Delivery Technology
- Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
October 23, 2008
- Opexa Provides Additional Promising Data Including Statistically Significant Reduction in Disability With Tovaxin for the Treatment of Multiple Sclerosis
- SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
- Proteolix Presents Solid Tumor Clinical Trial Results for Carfilzomib at EORTC-NCI-AACR International Conference
- Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
- Exelixis Reports Encouraging Phase 1 Data for XL184 at EORTC-NCI-AACR Symposium
- Aradigm Presents Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Cystic Fibrosis at the North American Cystic Fibrosis Conference
- Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
- EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
- Auspex Pharmaceuticals Announces Positive Results from Clinical Study of SD-254, A Next-Generation Potential Treatment for Depression
- Isolagen, Inc. Provides Analysis of Data from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles
- Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
- Altus Pharmaceuticals Announces Presentation of Phase 3 Trizytek Efficacy Data at the North American Cystic Fibrosis Conference
- Cougar Biotechnology Presents Positive CB7630 Phase II Data at EORTC-NCI-AACR Symposium
- ARIAD Presents Preclinical Data on Deforolimus and Bicalutamide in Androgen-Independent Prostate Cancer
- ZIOPHARM Presents Darinaparsin Molecular Mechanism of Action and Preliminary Oral Administration Phase I Clinical Data at the EORTC-NCI-AACR Symposium
- DUSA Announces Results for Phase IIB Trial Of Levulan Photodynamic Therapy for Moderate to Severe Acne
- EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
- Study Results: Multiple Sclerosis Patients Have Significant and Sustained Reduction in Disability and Risk Of Relapse On Alemtuzumab Versus Approved Therapy, Rebif
- Report Finds Risks of Developing Alzheimer's and Parkinson's Diseases can be Dramatically Reduced
- Curis Announces Preclinical Efficacy Data for CUDC-305 at EORTC-NCI-AACR Symposium
- Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
- Nerviano Medical Sciences Invited by EORTC-NCI-AACR to Present the State-of-the-Art of Aurora
- MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
- Exelixis Reports Positive Phase 1 Data for XL228 at EORTC-NCI-AACR Symposium
- Positive Preclinical Data Demonstrating Anti-Tumor Activity of NKTR-105 (PEG-docetaxel) Presented at 20th EORTC-NCI-AACR Conference
- Chipscreen Biosciences and HUYA Bioscience Int'l Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
- Incyte to Host Webcast and Conference Call on October 26, 10:30 p.m. Eastern Time / 7:30 p.m. Pacific Time
- Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
October 24, 2008
- Infinity Pharmaceuticals Announces Preclinical Pancreatic Cancer Data for IPI-926 (Hedgehog Pathway Inhibitor) at EORTC-NCI-AACR Cancer Meeting
- Inspire Announces New Data from Denufosol Phase 3 Program at North American Cystic Fibrosis Conference
- PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients
- Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs
- Telmisartan (MICARDIS) as Effective as Ramipril But With Better Long-Term Tolerability in High-Risk Cardiovascular Asian Patients
- Key Data Presented for Gemin X Programs at the 20th Annual ENA Symposium
- Ardea Biosciences Presents Preclinical Data on its Lead MEK Inhibitor, RDEA119, Demonstrating Synergy with Other Anti-Cancer Agents in Multiple Tumor Types
- Ariad Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Mechanism-Based Activity in Solid Tumors
- Infinity's Hedgehog Pathway Inhibitor IPI-926 Demonstrates Significant Tumor Growth Inhibition in Human Pancreatic Cancer Model
- LAB Research's Hungarian site successfully completes GLP certificate i...
- MedImmune to Present Nine Abstracts on RSV and Influenza at 48th Annual ICAAC/46th Annual IDSA Meeting
- Oral Fumarate Reduces Disease Activity In Relapsing-Remitting Multiple Sclerosis, And Phase Iii Results Now Awaited
- Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis
- Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
- Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
October 27, 2008
- Array BioPharma's Oral p38 Inhibitor Demonstrates Significant Analgesic Benefit and Systemic Anti-Inflammatory Activity
- Concert Pharmaceuticals Announces Preclinical Results Suggesting Potential for Once Daily Dosing of Novel Oxazolidinone Antibiotic
- Panacos Presents Phase 2b Bevirimat Data at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
- Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
- Targanta Presents Efficacy and Safety Data for Oritavancin for the Treatment of Gram-Positive Complicated Skin and Skin Structure Infections (cSSSI)
- Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
- Longer-Lasting Restylane Beauty Results Confirmed
- BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
- Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
- Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
- Sunesis Announces Updated Clinical Data of Voreloxin in Platinum-Resistant Ovarian Cancer
- Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
- Enzon's HIF-1 Alpha Antagonist Shows Antitumor Activity
- PhytoMedical's In Vivo Toxicity and Efficacy Tests on Human Colon Cancer Deliver Promising Results
- Actemra (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
- Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
- Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer
- Rituxan Data in Patients with Rheumatoid Arthritis to Be Presented at the American College of Rheumatology Annual Scientific Meeting
- Evotec Reports Phase I Safety Data from Tyramine Interaction Study with EVT 302
- XOMA Presents Data On XOMA 052, An Anti-IL-1 Beta Antibody, in Rheumatoid Arthritis and Acute Gout Animal Models
- CombinatoRx Provides In-Depth Analysis from Phase 2b Knee Osteoarthritis Study of Synavive (CRx-102) with Clinical Investigators
- MethylGene Presents Preclinical Data for MGD290, a Hos2 Fungal Inhibitor, at Joint ICAAC/IDSA Annual Meeting
- New Phase III Study in Previously Untreated HIV Patients Showed Merck's Isentress (raltegravir) Reduced HIV Viral Load to Undetectable Levels, Comparable to Efavirenz, When Taken in Combination with Other Medicines
- Cimzia (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
- High-Dose Influenza Vaccine Shows Increased Immune Response Among Adults 65 Years of Age and Older
- Statins Show Promise for Blood Clot Prevention
- Ardea Biosciences Presents Preliminary Data from a Phase 1 Study of RDEA594 at the 2008 ACR/ARHP Annual Scientific Meeting
- Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
- Ardea Biosciences Presents Additional Phase 2a and Preclinical Data on its Lead HIV Product Candidate, RDEA806, at the 48th Annual ICAAC/IDSA 46th Annual Meeting
- Pfizer’s Novel HIV/AIDS Treatment Selzentry (Maraviroc) Demonstrates Increased Efficacy Rate In Treatment-Naïve HIV Patients
- New Study Supports Use of Levaquin as a Guideline-Concordant Antibiotic for the Treatment of Community-Acquired Pneumonia (CAP)
- Nanoemulsion-Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen
- NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy
- Phase I/II Data Show that GSK’s Altabax (retapamulin ointment), 1% Decolonizes Staphylococcus aureus from Nasal Passages
- Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
- Bio-Quant Awarded Full AAALAC Accreditation
- Enbrel (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
- One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
- "Cancer Research" Journal Publishes Successful Angiogenesis Study Using Optimata's Technology
- GPC Biotech Presents New Pre-Clinical Data on RGB-286638 Broad-Spectrum Kinase Inhibitor at EORTC-NCI-AACR Meeting
- New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria
- Zosano Pharma, Inc. Announces Positive Results of Phase 2 Osteoporosis Study
- Publication on 'Tregitopes' in Blood Journal of October 2008
- Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
- Epistem to Present Plucked Hair Biomarker Data at ASCO-NCI-EORTC Meeting
October 28, 2008
- Pivotal Phase III Data Confirm The Efficacy And Safety Of Arpida’s Intravenous Iclaprim In Treating Patients With Complicated Skin And Skin Structure Infections
- QLT Announces Encouraging Phase II Data from Core Study of Punctal Plug Drug Delivery System
- Basilea presents research data at ICAAC/IDSA on novel antibiotic addressing the emerging threat from multi-resistant Gram-negative bacteria
- Forest Laboratories Presents Phase III Results on cSSSI at ICAAC
- GPC Biotech Presents New Pre-Clinical Data on RGB-286638 Broad-Spectrum Kinase Inhibitor at EORTC-NCI-AACR Meeting
- Galapagos NV (BE) - Nanocort demonstrates safety and good response in Phase I/II trial
- Geron Scientists and Collaborators Demonstrate Activity of Pancreatic Islet-Like Cells Derived From Human Embryonic Stem Cells in Diabetes
- Onconova Therapeutics Announces Publication of Positive Phase I Results for Lead Anticancer Compound in Journal of Clinical Oncology
- Panacos Announces Preliminary Results of Bevirimat Study 204
- Nuvo Research Presents Positive Phase III Study Results for Pennsaid at Leading Rheumatology Conference
- New Phase III Study in Previously Untreated HIV Patients Showed Raltegravir Reduced HIV Viral Load to Undetectable Levels, Comparable to Efavirenz, When Taken in Combination with Other Medicines
- Nycomed's Daxas Shows Encouraging Preliminary Results in Phase III COPD Studies
- ACZ885 Phase III data show rapid, sustained clinical remission in children and adults suffering from a group of rare, potentially life-threatening autoinflammatory diseases
- Nycomed’s Daxas shows encouraging preliminary results in phase III COPD studies
- Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
- Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim
- Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
- Gemin X Pan Bcl-2 Inhibitor Obatoclax Shows Biological and Clinical Activity in Heavily Pre-Treated Patients with Advanced CLL
- Argos Therapeutics Publishes Novel Approach to Improving Stimulation of Immunotherapeutic Pathways via Dendritic Cells
- Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim
- Provectus Announces Completion of Phase 1 Clinical Trial of PV-10 in Recurrent Breast Cancer
- BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
- 'Old Blood' Linked To Infection
- Antiseizure Drug Could be Fatal
- US Nicotine Addiction Reaches 15-Year High
- Premier Research Honored as 'Clinical Research Team of the Year' at 2008 GCPj Awards
- Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
- Newly Published Preclinical Study Shows Receptor BioLogix's Pan-HER Ligand Trap Has Broad Anti-Cancer Activity
- PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
- Active Biotech Presents New Data regarding the 57-57 SLE Project at American College of Rheumatology Meeting
- PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008
- Polymedix to Make Multiple Presentations of New Antibiotic Data at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
- Data Demonstrate Orencia (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis
- Gilead Announces Two-Year Clinical Data for Letairis (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
- MDS Pharma Services Takes Novel Steps to Recruit Patients for Alzheimer's Disease Study
- New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
- Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
- Recent Clinical Trial data for Nymox NX-1207 Drug to Be Presented at American Urological Association Meeting in Monterey on Thursday
- Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
- Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
October 29, 2008
- Data From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Presented at 19th Annual International Symposium on the Autonomic Nervous System
- Phase 2a Data for MEDI-528 Presented at CHEST 2008
- Alvine Pharmaceuticals Reports Positive Results With ALV003 in Phase 1 Trial of Therapy in Development for Celiac Disease
- Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic
- PraxisDirect 2.0 Allows Sites to Be More Productive
- Revotar Reports Positive Preclinical Data From a 4-month Dermal Toxicity Study
- Berger & Montague Announces Class Action Lawsuit Against Elan Corporation
- Powerful New Evidence Shows Statin Drugs Reduce Risk of Alzheimer's Disease
- Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
- Nebulized Perforomist Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
- Study Found That Long Term Use of Advair Diskus 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
- Pivotal Data Showed Symbicort Improved Lung Function in Adults with COPD
- Study Shows Vyvanse CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours
- PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
- Pneumococcal Vaccine Could Prevent Numerous Deaths, Save Costs During a Flu Pandemic, Model Predicts
- Rotavirus Infections Decline More than 70 Percent in Children in U.S.
- Generex to Host Satellite Symposium At World Congress on Controversies to Consensus in Diabetes, Obesity & Hypertension
- Humira Stops Joint Damage For 5 Years in Early RA
- Discovery Labs KL-4 Surfactant Data Presented At Two Key Medical Meetings
October 30, 2008
- StemCells, Inc. Announces Preclinical Results Showing its Proprietary Human Neural Stem Cells Can Prevent Vision Loss
- Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
- PPD Chairman of the Board Pledges $5 Million to Rutgers' Ernest Mario School of Pharmacy
- Telik Announces Top-Line Results From Assist-5 Trial of Telcyta in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
- PharmaNet Development Group Reports Third Quarter 2008 Preliminary Financial Results
- New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
- Genaera to Present at Therapeutic Area Partnerships 2008
- Successful Phase II Study Expands the Potential for Eprotirome in Dyslipidemia Treatment
- AMRI Presents Preclinical Data for Tubulin Inhibitor, ALB109564(a), at EORTC-NCI-AACR Symposium
- Non-Brain Penetrant CB1 Antagonists from Jenrin Discovery Show Beneficial Effects in Treating Diabetes and Obesity
- TCT2008 Concludes with Presentation of Positive Data for the Cypher Sirolimus-eluting Coronary Stent
- Toxicity of Breast Cancer Treatment Can be a Marker of its Success (ATAC Trial)
- Dow Pharmaceutical Sciences, Inc. to Present Scientific Poster at AAPS Evaluating the Affect of Flow Rate, Tissue Thickness and Receptor Phase Type on Drug Penetration When Appied Topically to Human Dermatomed and Dermis Only Skin
- Breast Cancer Patients Take DNA Test to Determine Best Treatment
- Biothera to Present Imprime PGG Clinical Trial Results at the International Society for Biological Therapy of Cancer
- Nymox NX-1207 Data Presented Today at American Urological Association Meeting in Monterey
- Non-Brain Penetrant CB1 Antagonists from Jenrin Discovery Show Beneficial Effects in Treating Diabetes and Obesity
- Researchers Identify Mechanism and Possible Drug Treatment for Growth of Nerve Tumors in Nerofibromatosis
- Generex Biotechnology Comments on New ADA/EASD Consensus Algorithm for Type 2 Diabetes Treatment
- New Cimzia Study Published in Arthritis & Rheumatism Shows Rapid Reduction of Symptoms and Inhibition of Joint Damage Progression in Rheumatoid Arthritis
- Study Identifies Three Effective Treatments for Childhood Anxiety Disorders
October 31, 2008
- Four Pralatrexate (PDX) Studies Accepted for Presentation at the 50th Annual Meeting of the American Society of Hematology
- Pervasis Therapeutics to Present Data from Phase 1 and 2 Clinical Trials of Vascugel at the American Society of Nephrology 41st Annual Meeting and Scientific Exposition
- Welichem Reports Positive Phase IIa Clinical Results
- Large-Scale Survey Reveals Low Sexual Desire Most Common Distressing Female Sexual Problem, Affecting Up to One in 10 Women
- New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
- Warfarin Sensitivity Study Results Update on Proposed Issue of American Depositary Shares
- Argos Therapeutics to Discuss Personalized Dendritic Cell Immunotherapy Process at iSBTc Annual Meeting
- Gemin X Announces Data Presentation for its Novel, Targeted Cancer Therapy Obatoclax at the 26th Chemotherapy Foundation Symposium
- Celldex Presents Results from Phase 1 Studies of CDX-1307 with GM-CSF
